Observational Study Evaluating Long-term Health Outcomes of Canadian Patients on an Active Drug-treatment

Brief summary

This is an open-label, postmarketing, observational study to document health outcomes, in Canadian patients with advanced Parkinson's disease and long-term treatment with an active drug (active drug intestinal gel).

Observational study

Parkinson Disease (PD)
88 patients
Protocol ID:
Observational model:
Time perspective:

Would you like to know more about this trial?

Yes, please contact me

Eligibility criteria

Participant attributes:
Male and Female


From 18 Years to 99 Years.

Inclusion Criteria:

- Diagnosed with advanced Parkinson's Disease

- Prescribed Duodopa by his/her treating physician.

Exclusion Criteria:

- Patients who were previously treated with Duodopa.

- Presence of other condition that, in the opinion of the treating physician, prohibits
the patient from participating in the study or obscures the assessment of the
treatment of advanced PD.

All the cities where the clinical studies are located

Calgary - T2N 4Z6
Edmonton - T6G 2X8
Hamilton - L8L 2X2
Kingston - K7L 2V7
London - N6A 5A5
Ottawa - K1H 8L6
Toronto - M5T 2S8
Montreal - H3G 1A4
Montréal - H2X 0A9
Quebec City - G1J 1Z4
Quebec City - G6V 3Z1
Quebec City - G1J 1Z4
Quebec City - G6V 3Z1
Sherbrooke - J1H 5N4
Winnipeg - R2H 2A5